Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age

Blood

Volumn 102, Issue 1, 2003, Pages 69-77

  Mileshkin, Linda ^b   Biagi, James J ^b   Mitchell, Paul ^b   Underhill, Craig ^b   Grigg, Andrew ^b   Bell, Richard ^b   McKendrick, Joe ^b   Briggs, Peter ^b   Seymour, John F ^b   Lillie, Kate ^b   Smith, Jennifer G ^b   Zeldis, Jerome B ^b   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CREATININE; INTRON (TM); LACTATE DEHYDROGENASE; THALIDOMIDE;

ADULT; AGE; AGED; ANOREXIA; ANXIETY DISORDER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONSTIPATION; CREATININE BLOOD LEVEL; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPONATREMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; SENSORY NEUROPATHY; SINUS BRADYCARDIA; SOMNOLENCE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

EID: 0038305911     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2846     Document Type: Article

References (45)

1. Durie, BG, The epidemiology of multiple myeloma. Semin Hematol. 2001;38:1-5.
2. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002; 100:755-760.
3. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109: 89-96.
4. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers, Ann Oncol. 2001;12:987-990.
5. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.
6. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol. 2001;115:605-608.
7. Blade J, Esteve J, Rosinol L, et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol. 2001;28:588-592.
8. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001; 86:404-408.
9. Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug. Br J Haematol. 2000;108:391-393.
10. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897-901.
11. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma, Leukemia. 2001; 15:1274-1276.
12. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma, Haematologica. 2002;87:408-414.
13. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advance multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J. 2002;3:185-192.
14. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989;320:1197-1200.
15. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 1989;320:1211-1212.
16. Treon SP, Maimonis P, Bua D, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000;96:3147-3153.
17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
18. Joshua DE, Penny R, Matthews JP, et al. Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol. 1997;97:38-45.
19. Stat Xact 5.0.3. Cambridge, MA: Cytel Software; 2001.
20. S-plus 2000. Seattle, WA: MathSoft; 1999.
21. SPSS Advanced Statistics 11.0.1. Chicago, IL: SPPS; 2001.
22. Johnston RE,Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002;43:351-354.
23. Pini M, Baraldi A, Pietrasanta D, et al. Low-dose of thalidomide in the treatment of refractory myeloma. Haematologica. 2000;85:1111-1112.
24. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399-403.
25. Neben K, Moehler T, Benner A, Kraemer A, Ho A, Goldschmidt H. Dose-dependent effect of thalidomide (THAL) on overall survival (OS) in relapsed and refractory multiple myeloma (MM) [abstract]. Blood. 2001;100:690a.
26. Wechalekar A, Sutton D, Voralia M, Stewart A, Chen C. Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma [abstract]. Blood. 2001;100:684a.
27. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715.
28. Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging. 2002;19:85-100.
29. Carli PM, Bailly F, Tavernier C, Milan C, Heudes D, Lavault JF. Multiple myeloma: epidemiological features in a well-defined population in Burgundy, France. Int J Epidemiol. 1989;18:330-333.
30. Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst. 1982;68:729-733.
31. Blade J, Munoz M, Fontanillas M, et al. Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing. 1996;25:357-361.
32. Riccardi A, Mora O, Brugnatelli S, et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospectiverandomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 1998;77:485-491.
33. Froom P, Quitt M, Aghai E. Multiple myeloma in the geriatric patient. Cancer. 1990;66:965-967.
34. Wisloff F, Andersen P, Andersson TR, et al. Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway, I. Eur J Haematol. 1991;47:333-337.
35. Cohen HJ, Bartolucci A. Age and the treatment of multiple myeloma: Southeastern Cancer Study Group experience. Am J Med. 1985;79:316-324.
36. Clavio M, Casciaro S, Gatti AM, et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica. 1996;81:238-244.
37. Rodon P, Linassier C, Gauvain JB, et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol. 2001;66:11-17.
38. Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25:533-539.
39. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600-607.
40. Leger CS, Bredeson C, Keams B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000;6:204-210.
41. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51-54.
42. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol. 2002;20:1429-1430.
43. Richardson P, Schlossman R, Hideshima T, et al. A phase I study of oral CC5013, an immunomodulatory thalidomide (Thai) derivative, in patients with relapsed and refractory multiple myeloma (MM) [abstract]. Blood. 2001;100:3225a.
44. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991-995.
45. Rajkumar SV, Hayman S, Gertz, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.